Accéder au contenu
Merck

The C2 domain of calpain 5 contributes to enzyme activation and membrane localization.

Biochimica et biophysica acta. Molecular cell research (2021-04-04)
Vimala Bondada, Jozsef Gal, Charles Mashburn, David W Rodgers, Katherine E Larochelle, Dorothy E Croall, James W Geddes
RÉSUMÉ

The enzymatic characteristics of the ubiquitous calpain 5 (CAPN5) remain undescribed despite its high expression in the central nervous system and links to eye development and disease. CAPN5 contains the typical protease core domains but lacks the C terminal penta-EF hand domain of classical calpains, and instead contains a putative C2 domain. This study used the SH-SY5Y neuroblastoma cell line stably transfected with CAPN5-3xFLAG variants to assess the potential roles of the CAPN5 C2 domain in Ca2+ regulated enzyme activity and intracellular localization. Calcium dependent autoproteolysis of CAPN5 was documented and characterized. Mutation of the catalytic Cys81 to Ala or addition of EGTA prevented autolysis. Eighty μM Ca2+ was sufficient to stimulate half-maximal CAPN5 autolysis in cellular lysates. CAPN5 autolysis was inhibited by tri-leucine peptidyl aldehydes, but less effectively by di-Leu aldehydes, consistent with a more open conformation of the protease core relative to classical calpains. In silico modeling revealed a type II topology C2 domain including loops with the potential to bind calcium. Mutation of the acidic amino acid residues predicted to participate in Ca2+ binding, particularly Asp531 and Asp589, resulted in a decrease of CAPN5 membrane association. These residues were also found to be invariant in several genomes. The autolytic fragment of CAPN5 was prevalent in membrane-enriched fractions, but not in cytosolic fractions, suggesting that membrane association facilitates the autoproteolytic activity of CAPN5. Together, these results demonstrate that CAPN5 undergoes Ca2+-activated autoproteolytic processing and suggest that CAPN5 association with membranes enhances CAPN5 autolysis.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Roche
Cocktail d'inhibiteurs de protéases sans EDTA Mini cOmplete, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Sigma-Aldrich
Anticorps monoclonal ANTI-FLAG® M2 antibody produced in mouse, clone M2, purified immunoglobulin (Purified IgG1 subclass), buffered aqueous solution (10 mM sodium phosphate, 150 mM NaCl, pH 7.4, containing 0.02% sodium azide)
Sigma-Aldrich
MG-132, en solution prête à l′emploi, ≥90% (HPLC)
Sigma-Aldrich
Anticorps monoclonal anti-β-actine antibody produced in mouse, clone AC-74, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
AEBSF, Hydrochloride, AEBSF, CAS 30827-99-7, is a specific irreversible inhibitor of chymotrypsin, kallikrein, plasmin, thrombin, trypsin, and related thrombolytic enzymes. A nontoxic alternative to PMSF and DFP.
Sigma-Aldrich
PD 150606, ≥97% (HPLC)
Sigma-Aldrich
Calpain Inhibitor IV, The Calpain Inhibitor IV controls the biological activity of Calpain. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.
Sigma-Aldrich
Calpain Inhibitor III, The Calpain Inhibitor III, also referenced under CAS 88191-84-8, controls the biological activity of Calpain. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.